Intellegens, a startup that has been incorporated with the University of Cambridge, has formed its first partnership for the use of the startup’s technology.

The new artificial intelligence technology, Alchemite, employs machine learning to provide a new way of analysing matrices and databases for companies.

“Alchemite is the first in a series of application specific AI modules that we are developing at Intellegens,” Dr Gareth Conduit, CTO and Co-founder of Intellegens said to Business Weekly. “These will be designed to address specific, high value, data analysis bottlenecks that we are uncovering through our discussions with existing and potential customers. With these new modules we intend to pursue new business opportunities in both the Life Sciences and other sectors.”

The artificial intelligence technology was developed by Conduit at the Cavendish Laboratories through his research. The Cambridge startup’s new collaboration is with e-Therapeutics, a company working on drug discovery using network methods.

“There is an increasing realisation that there is a huge amount of value locked in the massive databases that underpin most commercial organisations,” Co-founder and CEO of Intellegens, Ben Pellegrini said. “Through Intellegens, these companies now have a way to extract that value, using a proven method that is scalable, objective and meaningful. We believe our technology can help e-Therapeutics in its search for better and more potent drug candidates.”

e-Therapeutics will employ the use of Alchemite to provide more accurate predictions among other uses for their provided services.

“We already utilise machine learning heavily in our discovery platform to augment empirical biological and chemical data,” Dr Jonny Wray, head of discovery informatics at e-Therapeutics said. “Our partnership with Intellegens will enhance and extend our internal capabilities at the cutting edge of AI research and application.”

(Picture courtesy: www.intellegens.co.uk)